Compare Pfizer Inc (PFE) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Xylem, Inc. — how do they compare? Pfizer Inc trades at $27.76 (market cap $158.56B), while Xylem, Inc. trades at $102.3 (market cap $23.81B). The key difference: Pfizer Inc is far larger — about 6.7× Xylem, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Xylem, Inc. for 50 Days on average.
| PFE | XYL | |
|---|---|---|
Market Cap | $158.56B | $23.81B |
Volume | 44,138,282 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $29.02 | $152.95 |
52-Week Low | $23.67 | $100.92 |
Typical Hold Time | 158 Days | 50 Days |
Enterprise Value | $210.06B | $25.59B |
Dividend Yield | 6.18% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results due October 27. Revenue grew to $9.04B in 2025, with net income margin improving to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
Outlook remains positive due to strong water-solutions demand and margin expansion, though near-term sentiment is cautious amid China weakness and higher debt from recent note offerings. The consensus price target of $149.13 implies significant upside, but investors should monitor execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
